In a recent phase II study in which patients with NSCLC were randomized to MetMab (an anti-MET antibody) plus erlotinib versus erlotinib alone, increased expression of MET protein was associated with improved progression-free survival (HR = 0.53, P = 0.04: 1.5 months to 2.9 months) and overall survival (HR = 0.37, P = 0.002: 3.8 months to 12.6 months) in patients who received MetMAb and erlotinib [68]. This evidence concerns the gene MET and non-small cell lung carcinoma.